Daewoong Pharmaceutical acquires anti-aging platform from Turn Biotechnologies

Daewoong Pharmaceutical said Thursday it had acquired technology assets and related rights from Turn Biotechnologies through an auction bid, marking a major step into therapies targeting aging-related diseases.

At the center of the acquisition is Turn Biotechnologies’ ERA platform, a partial reprogramming technology that uses mRNA-delivered reprogramming factors to restore aged cells to a younger and healthier state while preserving their original cellular identity.

Unlike full reprogramming app